Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

Biochemical and Biophysical Research Communications

Volumn 356, Issue 2, 2007, Pages 323-328

  Roskoski Jr , Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

Bevacizumab; Cancer therapy; Colorectal cancer; Flt 3; Gastrointestinal stromal tumors; Leukemia; Renal cell cancer; SU 10944; SU 11248; SU 5416; SU 6668; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; COLONY STIMULATING FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SU 10944; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CAPILLARY ENDOTHELIUM; COLORECTAL CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PERICYTE; PRIORITY JOURNAL; SHORT SURVEY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; HUMANS; INDOLES; MICE; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947416658     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.156     Document Type: Short Survey

References (29)

1. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
2. Roskoski Jr. R. Vascular endothelial growth factor (VEGF) signaling during tumor progression. Crit. Rev. Oncol. Hematol. (2007) available online 26 February 2007 doi:10.1016/j.critrevonc.2007.01.006. [A comprehensive review of the discovery of the VEGF family of ligands and the VEGF receptors.]
3. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364 [A landmark paper first describing the angiogenic switch.]
4. Pietras K., Sjoblom T., Rubin K., Heldin C.H., and Östman A. PDGF receptors as cancer drug targets. Cancer Cell 3 (2003) 439-443
5. Östman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15 (2004) 275-286
6. Roskoski Jr. R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem. Biophys. Res. Commun. 338 (2005) 1307-1315
7. Camps C., Sirera R., Bremnes R.M., Garde J., Safont M.J., Blasco A., Berrocal A., Sanchez J.J., Calabuig C., and Martorell M. Analysis of c-kit expression in small cell lung cancer: prevalence and prognostic implications. Lung Cancer 52 (2006) 343-347
8. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3 (2003) 650-665
9. Chitu V., and Stanley E.R. Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 18 (2006) 39-48
10. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
11. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7 (2005) 513-520
12. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
13. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333 (2005) 328-335
14. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., and Tang C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 41 (1998) 2588-2603
15. Manley P.W., Bold G., Bruggen J., Fendrich G., Furet P., Mestan J., Schnell C., Stolz B., Meyer T., Meyhack B., Stark W., Strauss A., and Wood J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697 (2004) 17-27
16. Kim D.W., Jo Y.S., Jung H.S., Chung H.K., Song J.H., Park K.C., Park S.H., Hwang J.H., Rha S.Y., Kweon G.R., Lee S.J., Jo K.W., and Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 91 (2006) 4070-4076
17. Krystal G.W., Honsawek S., Kiewlich D., Liang C., Vasile S., Sun L., McMahon G., and Lipson K.E. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. 61 (2001) 3660-3668
18. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., and Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
19. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., and Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2 (2003) 471-478
20. Patel N., Sun L., Moshinsky D., Chen H., Leahy K.M., Le P., Moss K.G., Wang X., Rice A., Tam D., Laird A.D., Yu X., Zhang Q., Tang C., McMahon G., and Howlett A. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J. Pharmacol. Exp. Ther. 306 (2003) 838-845
21. Mendel D.B., Laird A.D., Smolich B.D., Blake R.A., Liang C., Hannah A.L., Shaheen R.M., Ellis L.M., Weitman S., Shawver L.K., and Cherrington J.M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15 (2000) 29-41
22. Laird A.D., Vajkoczy P., Shawver L.K., Thurnher A., Liang C., Mohammadi M., Schlessinger J., Ullrich A., Hubbard S.R., Blake R.A., Fong T.A., Strawn L.M., Sun L., Tang C., Hawtin R., Tang F., Shenoy N., Hirth K.P., McMahon G., and Cherrington J.M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60 (2000) 4152-4160
23. 50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
24. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., and Rini B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006) 16-24
25. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., and McDonald D.M. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116 (2006) 2610-2621
26. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs. 15 (2006) 553-561
27. Herbst R.S., Bajorin D.F., Bleiberg H., Blum D., Hao D., Johnson B.E., Ozols R.F., Demetri G.D., Ganz P.A., Kris M.G., Levin B., Markman M., Raghavan D., Reaman G.H., Sawaya R., Schuchter L.M., Sweetenham J.W., Vahdat L.T., Vokes E.E., Winn R.J., and Mayer R.J. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J. Clin. Oncol. 24 (2006) 190-205
28. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
29. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936